PUBLIC COMPANY
save$TLSATiziana Life Sciences Ltd
$TLSALondon, England, GBupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients
- phase2A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
- —Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
- phase2Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis
- phase1Safety, Tolerability and Immune Effects of the Nasal Foralumab in Healthy Human Volunteers
🐶 Hiring Signal
News
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with i…globenewswire_health · 14d ago
- Tiziana Life Sciences Announces Purchase of Shares by Chief Executive OfficerBOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with i…globenewswire_health · 14d ago
Data sources
last refreshed 9m ago
Found something off?
comments(0)
5-min edit window · permanent after that